Antibiotics may have been overused in COVID-19 patients: U.S. study

By Manas Mishra

(Reuters) – A majority of COVID-19 patients that were admitted to U.S. hospitals during the first few months of the pandemic were prescribed antibiotics even before a bacterial infection had been confirmed, a study showed on Wednesday.

The study by Pew Charitable Trusts suggests that such drugs were over-prescribed between February through July 2020, as doctors rushed to treat COVID-19 patients when treatment options were sparse.

Antibiotics do not fight viruses but are prescribed to treat secondary bacterial infections.

“Ultimately, what we’re really concerned about is what the data could mean about the long-term fight against antibiotic resistance,” said David Hyun, project director for Pew’s antibiotic resistance project.

The report, which included data from 5,838 hospital admissions, highlights the risk of prescribing antibiotics unnecessarily, which could speed up the emergence of drug-resistant ‘superbugs’.

Drug resistance is driven by the misuse and overuse of antibiotics and other antimicrobials, which encourages bacteria to evolve to survive by finding new ways to beat the medicines.

In the study, 52% of hospital admissions resulted in at least one antibiotic being prescribed. In contrast, 20% of those admitted with COVID-19 were diagnosed with a bacterial pneumonia, and 9% were diagnosed with urinary tract infections.

In 96% of cases, the patient received the first antibiotic within 48 hours of being admitted to a hospital.

The data did show that most patients who were given antibiotics immediately after hospitalization did not receive additional courses after 48 hours, suggesting some progress in efforts to limit overuse of antibiotics.

(Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)

U.S.-UK alliance targets the world’s deadliest superbugs

MRSA (Methicillin-resistant Staphylococcus aureus) bacteria strain is seen in a petri dish containing agar jelly for bacterial culture in a microbiological laboratory in Berlin March 1, 2008. MRSA is a drug-resistant "superbug", which can cause deadly infections. REUTERS/Fabrizio Bensch

By Kate Kelland

LONDON (Reuters) – Eleven biotech companies and research teams in Britain and the United States were awarded up to $48 million in funding on Thursday to speed development of new antibiotics powerful enough to take on the world’s deadliest superbugs.

The range of antimicrobial medicines able to kill the growing number of drug-resistant infections is dwindling and health experts warn that within a generation the death toll from such “superbug” infections could reach 10 billion.

Announcing its first funding, a new U.S.-U.K. alliance known as CARB-X, short for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, said it would invest an initial $24 million in 11 biotech companies pursing various projects to develop antibiotics and diagnostic. Another $24 million will be given in staged payments over three years as projects progress.

Added to private funds from the companies, the CARB-X funding could lead to an investment of more than $75 million in projects that show success, it said in a statement. Britain’s Wellcome Trust global health charity is committing 125 million pounds ($155.5 million) over five years.

Public health specialists have been warning for years that the world is facing an urgent global health threat from antibiotic-resistant superbug bacteria and that the pipeline of novel therapies to treat them is precariously thin.

Drug-resistant infections kill 700,000 people a year worldwide, and the last new antibiotic class to be approved for market was discovered in 1984.

With CARB-X funds, three of the 11 projects are working on potential new classes of antibiotics, while four are exploring new ways of targeting and killing bacteria.

Tim Jinks, head of drug resistant infection at the Wellcome Trust, said antibiotic resistance is already “a huge global health challenge” and is getting worse. “Without effective drugs, doctors cannot treat patients,” he said in a statement.

Kevin Outterson, CARB-X’s executive director and a professor of law at Boston University in the United States, added: “By accelerating promising research, it is our hope that we can speed up the delivery of new effective antibacterials, vaccines, devices and rapid diagnostics to patients who need them.”

(Editing by Alexander Smith)

California bill would require reporting of ‘superbug’ infections, deaths

anitbiotic-resistant bacteria

By Yasmeen Abutaleb

SAN FRANCISCO (Reuters) – A California state senator introduced a bill on Monday that would mandate reporting of antibiotic-resistant infections and deaths and require doctors to record the infections on death certificates when they are a cause of death.

The legislation also aims to establish the nation’s most comprehensive statewide surveillance system to track infections and deaths from drug-resistant pathogens. Data from death certificates would be used to help compile an annual state report on superbug infections and related deaths.

In September, a Reuters investigation revealed that tens of thousands of superbug deaths nationwide go uncounted every year. The infections are often omitted from death certificates, and even when they are recorded, they aren’t counted because of the lack of a unified national surveillance system.

“The (Reuters) story highlighted some of the problems that have come from the lack of information, the lack of reporting, especially deaths,” said state Senator Jerry Hill, who introduced the bill. “I wasn’t aware that on death certificates, antibiotic-resistant infections have never been called out.”

Because there is no federal surveillance system, monitoring of superbug infections and deaths falls to the states. A Reuters survey of all 50 state health departments and the District of Columbia found that reporting requirements vary widely.

California is among the states that do not require reporting of superbug-related deaths. A Reuters analysis of death certificates from 2003 to 2014 identified more than 20,000 deaths linked to the infections in California, the most of any state – and probably an undercount, given the unreliability of death certificate data.

Hill’s bill would require hospitals and clinical labs to submit an annual summary of antibiotic-resistant infections to the California Department of Health beginning July 1, 2018; amend a law governing death certificates by requiring that doctors specify on death certificates when a superbug was the leading or a contributing cause of death; and require the state Health Department to publish an annual report on resistant infections and deaths, including data culled from death certificates.

Hill introduced legislation in 2014 that would require reporting of superbug infections – not deaths. It was ultimately stripped down to mandate that all hospitals in California implement “stewardship” programs to prevent the overprescription of antibiotics that promotes drug resistance. Hill said the state medical association and other physician groups opposed the initial proposal.

The 2014 legislation followed a 2013 threat report from the Centers for Disease Control and Prevention, which estimated that at least 23,000 people in the U.S. die every year from antibiotic-resistant infections. A Reuters analysis of the agency’s math found that the numbers are based on such small sample sizes that they are mostly guesswork.

Hill has written several superbug-related bills that have been signed into law in recent years. Those include laws that regulate antibiotic use in livestock and others that mandate antibiotic stewardship programs in nursing homes and other healthcare facilities.

“We don’t know how (superbugs) affect California,” Hill said. “We could be overreacting in certain areas or underreacting in areas that could create real problems for people.”

(Edited by John Blanton)

Drug resistance in people and animals may push millions into poverty

The mcr-1 plasmid-borne colistin resistance gene has been found primarily in Escherichia coli, pictured.

By Alex Whiting

ROME (Thomson Reuters Foundation) – If drug-resistant infections in people and animals are allowed to spread unchecked, some 28 million people will fall into poverty by 2050, and a century of progress in health will be reversed, the World Bank said on Monday.

By 2050, annual global GDP would fall by at least 1.1 percent, although the loss could be as much as 3.8 percent – the equivalent of the 2008 financial crisis – the Bank said in a report released ahead of a high-level meeting on the issue at the United Nations in New York this week.

The rise of “superbugs” resistant to drugs has been caused partly by the increased use and misuse of antibiotics and other antimicrobial drugs in the treatment of people and in farming.

“We cannot afford to lose the gains in the last century brought about by the antibiotic era,” Tim Evans, the World Bank’s senior director for health, nutrition and population, told the Thomson Reuters Foundation.

“By any measure, the cost of inaction on antimicrobial resistance is too great, it needs to be addressed urgently and resolutely,” he said.

Greater quantities of antibiotics are used in farming than for treating people, and much of this is for promoting animal growth rather than treating sick animals, economist Jim O’Neill said in a report in May commissioned by the British government.

The O’Neill report estimated that drug-resistant infections could kill more than 10 million people a year by 2050, up from half a million today, and the costs of treatment would soar.


Farmers too will be greatly affected. The bank estimates that by 2050, global livestock production could fall by between 2.6 percent and 7.5 percent a year, if the problem of drug resistant superbugs is not curbed.

“Investments are urgently needed to establish basic veterinary public health capacities in developing countries,” Evans said.

Improved disease surveillance, diagnostic laboratories to ensure a disease is identified quickly, inspections of farms and slaughterhouses, training of vets, and oversight over the use of antibiotics are also needed, he said.

The U.N. Food and Agriculture Organization (FAO) estimates 60,000 tonnes of antimicrobials are used in livestock each year, a number set to rise with growing demand for animal products.

One of the most important ways to curb the spread of drug resistant microbes in food is to promote good farming practices, said Juan Lubroth, chief veterinary officer of FAO.

“I think this is where we can do most of our prevention – better knowledge on hygiene, vaccination campaigns, so these animals do not get sick and need antimicrobials (drugs),” Lubroth said in an interview from Rome.

Public demand for food that is uncontaminated, and better training of health professionals – doctors and vets – are also vital to help contain the problem, he added.

Hospitals and pharmaceutical companies also need to do more to treat their waste, he said.

The World Bank estimates that an investment of some $9 billion a year is needed in veterinary and human health to tackle the issue.

“The expected return on this investment is estimated to be between $2 trillion and $5.4 trillion … or at least 10 to 20 times the cost, which should help generate political will necessary to make these investments,” Evans said.

(Reporting by Alex Whiting, Editing by Ros Russell.; Please credit the Thomson Reuters Foundation, the charitable arm of Thomson Reuters, that covers humanitarian news, women’s rights, trafficking, corruption and climate change. Visit

‘Superbug’ infection related deaths are going uncounted

Kelly and Ryan Breaux sit holding a portrait of their deceased daughter Emma Breaux in their home in Breaux Bridge, Louisiana, on June 16, 2016. The husband and wife lost twins, Emma and Talon, to different superbugs that they contracted while in the neonatal unit at Lafayette General Hospital.

By Ryan McNeill, Deborah J. Nelson and Yasmeen Abutaleb

RICHMOND, Va. (Reuters) – Josiah Cooper-Pope, born 15 weeks premature, did fine in the neonatal intensive care unit for the first 10 days of his life.

Then, suddenly, his tiny body started to swell. Overnight, he grew so distended that his skin split.

His mother, Shala Bowser, said nurses at Chippenham Hospital in Richmond, Virginia, told her that Josiah had an infection and that she should prepare for the worst. On Sept. 2, 2010, she was allowed to hold him for the first and last time as he took his final breath. He was 17 days old.

What no one at the hospital told Bowser was that her newborn was the fourth baby in the neonatal unit to catch the same infection, methicillin-resistant Staphylococcus aureus, better-known as MRSA. It would sicken eight more, records show – nearly every baby in the unit – before the outbreak had run its course.

The shock of her son’s death came back to her when, after being contacted by Reuters earlier this year about the outbreak, Bowser went to Virginia’s Division of Vital Records to get a copy of Josiah’s death certificate. The cause of death: “Sepsis due to (or as a consequence of): Prematurity.” Sepsis is a complication of infection, but there was no mention of MRSA.

“My heart hurts,” Bowser said, sobbing. “I saw what this did to him. And then they just threw a bunch of words on the death certificate.”

According to their death certificates, Emma Grace Breaux died at age 3 from complications of the flu; Joshua Nahum died at age 27 from complications related to a skydiving accident; and Dan Greulich succumbed to cardiac arrhythmia at age 64 after a combined kidney and liver transplant.

In each case – and in others Reuters found – death resulted from a drug-resistant bacterial infection contracted while the patients were receiving hospital care, medical records show. Their death certificates omit any mention of the infections.

Fifteen years after the U.S. government declared antibiotic-resistant infections to be a grave threat to public health, a Reuters investigation has found that infection-related deaths are going uncounted, hindering the nation’s ability to fight a scourge that exacts a significant human and financial toll.


Even when recorded, tens of thousands of deaths from drug-resistant infections – as well as many more infections that sicken but don’t kill people – go uncounted because federal and state agencies are doing a poor job of tracking them. The Centers for Disease Control and Prevention (CDC), the go-to national public health monitor, and state health departments lack the political, legal and financial wherewithal to impose rigorous surveillance.

As a result, they miss people like Natalie Silva of El Paso, Texas, who contracted a MRSA (pronounced MER-suh) infection after giving birth. She died from infection-related complications nearly a year later, at age 23.

Silva’s sisters fought a successful battle to get the hospital to cite MRSA on her death certificate. Still, her death went uncounted: The Texas health department doesn’t track deaths like hers from antibiotic-resistant infections, and neither does the CDC.

As America learned in the battle against HIV/AIDS, beating back a dangerous infectious disease requires an accurate count that shows where and when infections and deaths are occurring and who is most at risk. Doing so allows public health agencies to quickly allocate money and manpower where they are needed. But the United States hasn’t taken the basic steps needed to track drug-resistant infections.

“You need to know how many people are dying of a disease,” said Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics Policy, a Washington-based health policy research organization. “For better or worse, that’s an indicator of how serious it is.”

Drug-resistant infections are left off death certificates for several reasons. Doctors and other clinicians get little training in how to fill out the forms. Some don’t want to wait the several days it can take for laboratory confirmation of an infection. And an infection’s role in a patient’s death may be obscured by other serious medical conditions.

There’s also a powerful incentive not to mention a hospital-acquired infection: Counting deaths is tantamount to documenting your own failures. By acknowledging such infections, hospitals and medical professionals risk potentially costly legal liability, loss of insurance reimbursements and public-relations damage.

Doctors and other clinicians also may simply not understand the importance of recording the infections. Sandy Tarant, the doctor who signed Josiah Cooper-Pope’s death certificate, told Reuters that he thought “it didn’t matter” whether he cited a MRSA infection.

Legally, he’s right. Most states don’t require doctors to specify whether MRSA was a factor in a death. Washington and Illinois are exceptions.

State laws govern how death certificates are filled out. Most use a model law that mandates financial penalties for anyone who deliberately makes a false statement on the document, said Patricia Potrzebowski, director of the National Association for Public Health Statistics and Information Systems. The penalties are often small and rarely enforced, she said.


Not even the CDC has a good handle on the extent of the problem. The agency estimates that about 23,000 people die each year from 17 types of antibiotic-resistant infections and that an additional 15,000 die from Clostridium difficile, a pathogen linked to long-term antibiotic use.

The numbers are regularly cited in news reports and scholarly papers, but they are mostly guesswork. Reuters analyzed the agency’s math and found that the estimates are based on few actual reported deaths from a drug-resistant infection.

The agency leaned heavily on small samplings of infections and deaths collected from no more than 10 states in a single year, 2011. Most didn’t include populous areas such as Florida, Texas, New York City and Southern California.

From those small samples, the CDC then extrapolated most of its national estimates, introducing so much statistical uncertainty into the numbers as to render them useless for the purposes of fighting a persistent public health crisis.

Describing the estimates to Reuters, even CDC officials used words like “jerry-rig,” “ballpark figure” and “a searchlight in the dark attempt.”

Michael Craig, the CDC’s senior adviser for antibiotic resistance coordination and strategy, said the agency, pressured by Congress and the media to produce “the big number,” settled on “an impressionist painting rather than something that is much more technical.”

In a statement emailed to Reuters, CDC officials said they released the 2013 estimates report “despite its limitations because of our profound concern about the seriousness of the threat.” The agency said it is working on improving its estimates.

The numbers of uncounted deaths from drug-resistant infections “speak to what can happen when we don’t allocate the necessary resources to bolster … our public health safety network,” said Senator Sherrod Brown. “When we see discrepancies in reporting, are unable to finance a workforce to monitor infections, and can’t even soundly estimate the number of Americans that die from [antibiotic-resistant infections] each year, we know we have a problem.”

The Ohio Democrat recently introduced a bill that would require the CDC to collect more and better data on superbug infections and death rates.

In the absence of a unified national surveillance system, the onus of monitoring drug-resistant infections and related deaths falls on the states. A Reuters survey of the health departments of all 50 states and the District of Columbia found wide variations in how they track seven leading “superbug” infections – if they do so at all.

Only 17 states require notification of C. difficile infections, for example, while just 26 states and Washington, D.C., do the same for MRSA. Fewer than half require notification of infections by carbapenem-resistant Enterobacteriaceae (CRE), a family of pathogens that the CDC has deemed an “urgent threat.” CRE gained notoriety when more than 200 people were sickened through contaminated medical scopes in hospitals from 2012 to 2015.

Twenty-four states and the District of Columbia – an area comprising 3 of every 5 Americans – said they do not regularly track deaths due to antibiotic-resistant infections. In contrast, all 50 states require reporting of deaths from AIDS. Deaths from hepatitis C and tuberculosis are also closely tracked.


States that said they do track deaths generally do so for only a few types of drug-resistant infections and not consistently. In the survey, they reported a combined total of about 3,300 deaths from 2003 to 2014.

That’s a tiny fraction of the actual toll: A Reuters analysis of death certificates found that nationwide, drug-resistant infections were mentioned as contributing to or causing the deaths of more than 180,000 people during the same period. To conduct the analysis, Reuters worked with the CDC’s National Center for Health Statistics’ Division of Vital Statistics to search text descriptions on death certificates to identify relevant deaths.

Among the states that don’t require reporting of superbug deaths is California, the nation’s most populous state. The Reuters analysis identified more than 20,000 deaths linked to drug-resistant infections during the 12-year period, the most of any state. A health department spokeswoman said the state legislature authorized the department to be notified of infections, but not deaths.

Tennessee doesn’t require notification of deaths, either. The Reuters analysis found more than 5,500 deaths linked to superbugs there, more than half of them MRSA-related.

“We know we have a problem with MRSA in Tennessee,” said Marion Kainer, the state’s director of antimicrobial resistance programs. Requiring hospitals to report deaths is more than the department can take on right now, she said. “We have a significant problem getting clinicians to report just the disease,” she said. “It’s grossly under-reported.”

The totals from the Reuters analysis also indicate that the problem is getting worse nationwide, as the number of deaths from drug-resistant infections more than doubled from 8,600 in 2003 to about 16,700 in 2014. (Some of that increase could be the result of clinicians’ increased awareness of the infections.)

Death certificates aren’t a perfect measure. They can be wrong: Cause of death often is a judgment call by clinicians, who may blame a drug-resistant infection in error. More likely, they undercount drug-resistant deaths, as cases like that of Josiah Cooper-Pope show. Just how far under is impossible to know.

But there are clues: Connecticut, with a grant from the CDC, is the only state that closely monitors MRSA deaths. It logged 2,084 deaths from drug-resistant infections from 2003 to 2014, all but 10 from MRSA. That’s nearly twice the number of deaths from MRSA in the state that Reuters found in its death certificate analysis.

One reason for the disparity is that the state’s count includes anyone who died with MRSA, even if it wasn’t the cause of death, said Dr Matthew L. Cartter, Connecticut’s epidemiologist. He also said death certificates may undercount MRSA deaths because the physician may cite a general infection-related condition – death due to sepsis, for example – without mentioning the actual bacteria involved, or merely describe the mechanics of death, such as organ failure or cardiac arrest.

For many victims’ relatives interviewed by Reuters, the death certificate held special significance. They had watched an infection squeeze the life out of a loved one, often over several months and in gruesome ways. To find no official record of that on the death certificate came as a shock. It was as if the killer got away.


Dan Greulich’s medical records show that, after his transplant operation, he spent five months battling drug-resistant infections that left him so debilitated he asked to be taken off of life support. He died in June 2012. By the time of his death – due to “cardiac arrhythmia,” according to the death certificate – the cost of his care at UCLA Medical Center amounted to more than $5 million.

“When the doctor wouldn’t count him as one of the people who die from hospital-acquired infections, I was outraged,” said Rae Greulich, his widow. She considered suing the hospital but never did.

UCLA Medical Center declined to comment.

Joshua Nahum’s recovery from a skydiving accident on Sept. 2, 2006, was going so well at Longmont United Hospital in Colorado that he was transferred to Northern Colorado Rehabilitation Hospital a month later in preparation for going home.

Within days, his temperature spiked, his condition deteriorated, and he was transferred back to Longmont. There, he was diagnosed with meningitis from Enterobacter aerogenes, a virulent drug-resistant pathogen spread almost exclusively in healthcare settings.

By the time he died on Oct. 22, the swelling in his brain had made him a quadriplegic, said his father, Armando Nahum. The infection was “the most immediate cause of his death,” his neurosurgeon, Dr E. Lee Nelson, told Reuters.

His death certificate said he died of “Delayed Complications of Craniocerebral Injuries” from the accident. “I remember being dumbfounded. ‘Are you serious?’” Nahum said. “All I asked was that they write the truth – that Josh died of an infection.”

Hospital records obtained by the family show he also contracted meningitis from a methicillin-resistant Staphylococcus epidermidis infection while at Longmont. Similar to MRSA, it is a potentially lethal drug-resistant bug.

In an email statement, Nancy Driscoll, chief nursing officer at Longmont United, said an independent review concluded that Nahum’s care “was appropriate.” She did not respond to questions about how he contracted the infections. Northern Colorado Chief Executive Officer Beth Bullard declined to discuss the case.

Because Nahum died nearly two months after the accident, the cause of death was certified by the Boulder County coroner’s office. Dr John E. Meyer, deputy coroner at the time, signed the death certificate. He told Reuters that he did not recall the case but would not have thought to specify that the complication was an infection.

“There’s certainly no rule that I know of,” he said.

Patient safety groups petitioned the CDC in 2011 to add a question about hospital-acquired infections to its standard death certificate, which is used by many states.

CDC Director Dr Thomas Frieden wrote that he would consider including patient advocates in discussions the next time the agency revises its death certificate, but there were no plans to make any changes “in the near future.”

In a statement emailed to Reuters, Frieden said: “While death certificates provide helpful information, the unfortunate reality is that they don’t provide in-depth clinical information.”


Antibiotic-resistant bacteria have been around nearly as long as antibiotics. Alexander Fleming discovered penicillin, the first modern antibiotic, in 1928, saving millions of lives from infections that just a few years earlier would have been fatal. By 1940, researchers were reporting that bacteria had already developed resistance to the drug.

Modern science became locked in a war of one-upmanship with the microbial world. Researchers would develop a class of drugs to replace those that were becoming ineffective, and soon enough, bacteria would begin showing resistance to the new drugs – a problem worsened by widespread overprescription of antibiotics and their overuse in farm animals.

By the 1990s, drug-resistant infections had reached crisis proportions. Advances in medicine have been, paradoxically, a big reason for the worsening epidemic.

More people than ever are living with weak immunity: premature infants, the elderly, and people with cancer, HIV and other illnesses that were once fatal but are now often chronic conditions. That’s also why superbugs most often occur in hospitals, nursing homes and other healthcare facilities – places where susceptible populations are concentrated.

In 2001, a task force led by the CDC, the Food and Drug Administration and the National Institutes of Health declared antibiotic-resistant infections to be a grave public health threat and issued an action plan to tame the problem. The group’s recommendations included creating a national surveillance plan and speeding development of new antibiotics.

Yet not a single new class of antibiotics has been approved for medical use since 1987. Despite years of efforts to educate healthcare workers about infection control, multiple studies show that many still routinely flout even basic preventive measures, like hand-washing.

While the types of bacteria showing drug resistance have multiplied, the federal government requires hospitals to report infections for only two of them, MRSA bacteremia, or blood infection, and C. difficile. It requires limited reports on the others and relies on the states to fill in the gaps.

In 2014, the administration of President Barack Obama issued a new national action plan to combat antibiotic-resistant bacteria. Congress followed last year with a $160 million increase in the CDC’s budget to bolster research, drug development and surveillance of superbugs by the states.

But as Reuters found, surveillance carried out by the states can come up against strong institutional resistance and laws that shield the healthcare industry.

Under Virginia law, Chippenham Hospital should have reported its 2010 MRSA outbreak to the state Department of Health when the third baby in the neonatal intensive care unit tested positive for the bug, health department officials said. That was four days before newborn Josiah Cooper-Pope fell ill.

Instead, according to Virginia Health Department records and interviews with department officials, the hospital didn’t notify public health officials until nearly every baby in the unit had been infected – and then only by mail.

By that time, Josiah had been dead two weeks and another baby was in critical condition with a MRSA infection.

After persuading the hospital to temporarily close the unit and bringing the outbreak under control, Health Department investigators found that Chippenham hadn’t taken basic steps to prevent MRSA’s spread, such as training staff, scrubbing furniture and computers, and testing all infants in the nursery when the infection first surfaced.

Jennifer Stanley, a spokesperson for Hospital Corp of America, which owns Chippenham, said that since the outbreak, the hospital has put in place “aggressive infection prevention measures” and “intensive education and training.”

Virginia took no action against the hospital for the lethal outbreak.


The state can fine hospitals for violating regulations, but “this is not the approach [the Department of Health] typically follows,” said Maribeth Brewster, department spokesperson. Officials prefer “working closely” with hospitals to correct patient safety problems, she said, and a follow-up inspection at Chippenham Hospital found no regulatory violations, so no action was warranted.

In response to a Reuters public records request on the outbreak, the Health Department sent a copy of its investigation report in which the name and address of the hospital were blacked out.

The same was true for 22 more superbug outbreaks in Virginia healthcare facilities since 2007 that involved more than 130 patients, including 15 who died. State law prohibits the agency from identifying the location of outbreaks. At least 27 other states have similar laws or policies in place.

Disclosing the names of healthcare providers “would serve as a significant disincentive to the timely reporting of disease outbreaks,” said Brewster, the Virginia Health Department spokesperson.

Tarant, the doctor who signed Josiah’s death certificate, put it this way: “Things like this, if dealt with appropriately, are best if kept internally. I don’t think people want to see how the sausage is made.”

At a conference last year, hospital infection-control specialists told CDC officials that medical staff and internal review boards sometimes blocked them from reporting infections as required by state law or by the Centers for Medicare & Medicaid Services (CMS), which reduces payments to hospitals for preventable infections and high infection rates.

The specialists said medical staff sometimes were discouraged from testing patients with clear signs of infection – one of several tactics they said staff used to get around reporting rules.

Those complaints were detailed in a notice the CDC and CMS sent late last year to hospitals nationwide, warning them that offenders could be fined and cut off from federal funds for covering up infections they are legally required to disclose.

Officials said that due to database limitations, they did not know whether any facilities had been cited for underreporting infections since the notice was issued.

Acknowledging any infection caught in a hospital or other healthcare setting carries another risk: The paper trail can support a subsequent lawsuit.

Emma Grace Breaux and her twin brother, Talon, fell ill from infections shortly after they were born 12 weeks premature at Lafayette General Medical Center in Lafayette, Louisiana, in 2005. Talon died at 15 days old after becoming infected by a virulent strain of Pseudomonas aeruginosa, a ubiquitous bacteria that easily contaminates hospital equipment.

“The day we buried him, we found out about Emma’s infection,” said Kelly Breaux, their mother.

Emma had a MRSA infection. She survived, but with permanent damage to her heart, lungs and one leg.

Three and a half years later, Emma was in Florida to have her leg repaired when she came down with swine flu. It was too much for her heart and lungs. After a six-week battle, she died at Miami Children’s Hospital just shy of her fourth birthday. Her death certificate blamed flu-related pneumonia. Including MRSA as a cause of death “was not considered,” said Dr Sharon Skaletzky, who was at Miami Children’s at the time and signed the death certificate.

Talon’s case was clear-cut; his death certificate cited septic shock due to his hospital-acquired Pseudomonas infection as the cause of death.

Emma’s was more complicated. Her medical expenses alone eventually exceeded $4 million for repeated hospitalizations due to complications from her MRSA infection. The family sold their home, truck and other possessions to stay afloat while she underwent multiple operations.

A Louisiana appeals court ultimately ruled that MRSA was responsible for her death and in 2013 upheld a jury award of more than $6 million in damages and medical expenses for the twins.

Lafayette General Medical Center spokesperson Daryl Cetnar said no one with knowledge of the case was available.


Lack of a unified national surveillance system makes it next to impossible to count the number of drug-resistant infections, fatal or otherwise. Theoretically, deaths could be counted through the nation’s vital statistics.

Those numbers, compiled by the National Center for Health Statistics (NCHS), include births, marriages, divorces and, using data culled from death certificates, information on what is killing whom. The numbers are critical in determining how money is distributed for research and public health campaigns.

As examples in this article show, superbug infections are often omitted from death certificates. But even when they are recorded, NCHS can’t feed that information into vital statistics: The World Health Organization (WHO) classification system the agency uses lacks mortality codes for most drug-resistant infections, though it has codes for more than 8,000 other possible causes of death.

The CDC added codes for use in the United States for terrorism-related deaths a year after the Sept. 11, 2001, attacks. It could do the same for deaths from drug-resistant infections. Officials told Reuters the CDC is instead working to incorporate the codes into the WHO’s next revision of the international classification system. The revised system is expected to be completed in 2018 but not fully in use until the 2020s.

There are other ways to count deaths, such as searching the text of death certificates as Reuters did in its analysis with help from the NCHS. CDC officials told Reuters they now are exploring “how we might be able use literal text capture to get additional information on resistant infection deaths which could be useful for annual tracking.”

As it stands, the CDC has the National Healthcare Safety Network. Under this surveillance program, about 5,000 hospitals and in-patient rehabilitation facilities file quarterly reports on several types of healthcare-related infections as a condition of receiving Medicare and Medicaid payments.

But only two superbug infections are on the reportable list, MRSA bacteremia and C. difficile. The others are reported under only limited circumstances, such as when related to a hysterectomy or a catheter-associated urinary tract infection.

The reports are typically five to seven months old by the time they are logged, and thus aren’t useful for real-time surveillance. And the CDC doesn’t require facilities to report deaths. Determining cause of death is difficult and would entail extra training for hospital staff who fill out the forms and oversight, which the agency can’t afford, according to Dr Daniel Pollock, surveillance branch chief for the CDC’s Division of Healthcare Quality Promotion.

CDC Director Frieden, noting that there is “no simple way to code for drug-resistant infections” on death certificates, said the CDC “is supporting states’ efforts to respond to antibiotic resistance and help protect Americans from this threat.”

Just 16 state health departments told Reuters that they tally deaths from reportable antibiotic-resistant infections. Eight others track deaths only when they are part of an outbreak. (Pennsylvania and Georgia declined to answer the survey questions.)

Among states that don’t track deaths is Texas, where Natalie Silva contracted MRSA in November 2012 at Hospital Corp of America’s Del Sol Medical Center in El Paso. Two days after giving birth to a healthy boy by cesarean section, her incision began gushing blood, said her sister, Crystal Silva. Back at the hospital, Natalie Silva tested positive for MRSA.

Hospital staff assured Silva it was safe to continue holding and breastfeeding her week-old son, according to Crystal Silva and her other sister, Stephanie Hall. One month later, her son was in the neonatal intensive care unit battling his own MRSA infection, they said.

He survived. For Silva, the next few months brought a cascade of medical complications, records show. Multiple infections led to multiple surgeries that left her paralyzed. Hall recalled spending a Friday night in September 2013 at her sister’s bedside, painting Silva’s fingernails metallic blue and her toenails metallic purple, optimistic that her sister would return home.

Three days later, Silva died.

Silva’s doctors wanted to blame cardiac arrest on the death certificate, Silva’s sisters said.

Del Sol Medical Center declined to comment.

Silva’s family paid $3,000 for an autopsy that confirmed that the MRSA infection contributed to her death. Her death certificate lists cardiopulmonary arrest as the immediate cause of death, due to complications from a MRSA infection.

“She was 23 years old and healthy. We knew that MRSA played a huge role,” said Crystal Silva. “We had to fight for them to include it.”

In September last year, Hall filed a medical malpractice and wrongful death lawsuit against Del Sol in El Paso County District Court, alleging that the hospital was responsible for Silva’s MRSA infection and the fatal complications that followed. The lawsuit is seeking payment to Silva’s two children for the loss of their mother, loss of her wages while she was sick, medical costs and funeral expenses.

Christine Mann, spokeswoman for the Texas health department, said counting superbug deaths would require a formal statute or rule change in the state. “We prioritize our resources and attention toward taking public health action where it is most needed,” she said.

Natalie Silva’s was among about 10,000 deaths linked to antibiotic-resistant infections in Texas from 2003 to 2014, according to the Reuters analysis. Though her sisters succeeded in getting an honest reckoning on Silva’s death certificate, her death by superbug was never counted.

(Edited by John Blanton)

Spiders, snakes and scorpions join fight against superbugs

By Matthew Stock

(Reuters) – A British lab is searching for new medicines in the poisonous secretions of some of the world’s deadliest creatures, addressing the increasingly desperate challenge of finding viable new drugs.

Over-prescription and over-use in farming of antibiotics has given rise to so-called ‘superbugs’, multi-drug resistant infections that can evade even the medicines designed to kill them. Experts have warned since the 1990s that lethal super-bugs were on the horizon, but few drug makers have attempted to develop drugs against them.

Venomtech, based in south-east England, believe help could be found in the unlikeliest of sources; the venom of spiders, scorpions and snakes that is often fatal to humans. Millions of years of evolution has given these creature’s venom the ability to target and attack their prey while avoiding the body’s defenses. Venomtech scientists hope that an injected drug could perform the same function.

When broken down at the molecular level a tiny droplet of venom contains hundreds of individual components that could eventually be made into new drugs, explained Venomtech founder Steven Trim.

“The principle of Venomtech is separating venoms out into their component parts and targeting them to the right disease area,” Trim told Reuters.

He added that his drug discovery team was “putting the right venom for the right drug target so we maximize the hits – and a hit is an interesting peptide that might make it to a drug.”

Around 400 animals are kept at his lab in Kent, including about 70 species of tarantula and 30 species of scorpion. Many of these kill their prey with venoms that contain hundreds of protein molecules, some of which block nerve activity. Venomtech keep a number of invertebrates which can be deadly to humans, namely the black widow spider and deathstalker scorpion.

Trim, who worked for pharmaceutical company Pfizer before founding Venomtech, stressed that the venom extraction process causes no discernible harm to the creatures.

“We anesthetize the invertebrates, just to temporarily put them to sleep, it makes it safer for us because if they’re immobile they can’t bite us. But also it’s better for the animals as well. And using a very tiny electrical stimulation, just to contract the muscle and squeeze the gland we get a small amount of venom produced,” he said.

The venom extracted from each creature can be measured in micro-liters; a thousandth of a milliliter. Nevertheless, this tiny volume holds hundreds of useful molecules.

“The average scorpion will only produce 2 or 3 micro-liters. So it’s a really small amount. But in that small amount there’s a lot of interesting peptides; several hundred different components and several micro-grams of protein in there, so there’s plenty for us to work with,” Trim said. “We separate that out in a two phase process called high pressure liquid chromatography. And that gives us typically about a hundred fractions per venom, and each one of those fractions may contain 1 to 5 individual peptides. And it’s those individual peptides and proteins that are the real interesting things; these are the molecules that convey the biological activity of the venom.”

Working with scientists from nearby Canterbury Christ Church University, they’ve been screening their venom-derived ‘chemical library’ against different diseases.

Trim said they’ve had some extremely encouraging results.

“Some of them we found can kill bacteria, bacteria like E.Coli and Staphylococcus, so very relevant at the moment where modern medicines are failing. And we’re also finding venoms that are modifying and killing cancer cells,” he said, adding that Venomtech is now working with pharmaceutical companies to turn their venom discoveries into the next generation of drugs.